Skip to main content

Table 2 Clinical and laboratory characteristics of the studied cytogenetic groups

From: Clinical impact of early minimal residual disease detection at day 15 in precursor B-childhood acute lymphoblastic leukemia: an Egyptian experience

Parameter

t (9;22) n = (4)

t(1;19) n = (8)

11q23 rearrangement n = (4)

Age

 <1 year-

0

4

2

 1–9 years

2

4

2

> 10 years

2

0

0

Sex

 Male

4

6

2

 Female

0

2

2

Clinical data

 

 Hepatomegaly

4

8

2

 Splenomegaly

4

4

4

 Lymphadenopathy

4

8

0

 CNS infiltration

2

0

2

Laboratory data (at diagnosis)

Mean (± SD)

Mean (± SD)

Mean (± SD)

 TLC (× 109/L)

86.1 ± 48.9

87.4 ± 44.81

89.25 ± 17.04

 Hb (gm/dl)

6.7 ± 1.1

7.93 ± 2.12

9.05 ± 1.63

 Platelets(× 109/L)

46.5 ± 7.7

49.75 ± 34.07

55.50 ± 13.44

 Peripheral blood blasts (%)

29.0 ± 4.2

28.0 ± 28.93

18.50 ± 3.54

 Blasts in B.M (%)

68.5 ± 3.5

58.5 ± 18.27

63.5 ± 38.89

Laboratory data (at day 15 of induction)

Mean (± SD)

Mean (± SD)

Mean (± SD)

 TLC (× 109/L)

1.8 ± 1.4

1.25 ± 0.45

1.80 ± 1.41

 Hb (gm/dl)

7.7 ± 0.4

7.8 ± 1.14

7.85 ± 0.49

 Platelets(× 109/L)

110.5 ± 27.6

51.0 ± 29.46

69.5 ± 23.33

 Blasts in B.M (%)

12.5 ± 13.4

10.25 ± 7.5

13.50 ± 7.78

MRD status at day 15

 

 Good outcome

2

2

0

 Bad outcome

2

6

4

  1. TLC total leukocytic count, Hb hemoglobin, PB peripheral blood, BM bone marrow, SD standard deviation, n number